Retatrutide Dosage: Titration Schedule, Starting Dose, and Chart

Retatrutide dosing involves a once-weekly subcutaneous injection, progressing incrementally from a 2 mg starting dose to a 12 mg maximum. This gradual escalation occurs approximately every four weeks, with the full dosage reached in about four months. This schedule aligns with the drug's long half-life and the dose-related side effects discussed further below.

Retatrutide is an investigational peptide. It is not FDA-approved and remains in Phase 3 clinical trials, so there is no official prescribing information or approved dosing at this time. Eli Lilly reported the Phase 3 TRIUMPH-1 topline results in May 2026, but the drug is not commercially available and lacks approved dosing guidelines.

This article serves an educational purpose by detailing the dosing schedules observed in clinical trials and conventions reviewed within research and user communities. It does not constitute instructions for self-injection. Retatrutide functions as a triple agonist, simultaneously targeting the GLP-1, GIP, and glucagon receptors, offering a distinct mechanism compared to existing single- and dual-agonist medications. Clinical trials have assessed its use in obesity and type 2 diabetes. The glucagon receptor activation distinguishes it from semaglutide and tirzepatide. Dosing decisions for such a drug should be made by a licensed clinician familiar with your medical history.

Below is the one-line dosing progression used in trials: 2 mg for the initial four weeks, followed by 4 mg, 6 mg, 9 mg, and 12 mg. Each dose level is maintained for roughly four weeks before proceeding to the next. As the dose increases, so does weight loss, but the side effect profile also intensifies, which is why each dose is sustained long enough to stabilize before escalating. This approach requires patience, as the significant weight loss typically occurs after reaching the maintenance dose, not during the initial weeks. The retatrutide overview page provides a more detailed exploration of the mechanism and trial data.

The Phase 3 TRIUMPH ladder progressed in five distinct phases. Weeks 1 to 4: 2 mg. Weeks 5 to 8: 4 mg. Weeks 9 to 12: 6 mg. Weeks 13 to 16: 9 mg. Week 17 onward: 12 mg. Each dosage level was maintained for approximately four weeks prior to the next increment, with all participants initiating at the same 2 mg. This starting point was standardized and not adjusted based on weight, meaning a 250-pound individual and a 180-pound individual both commenced at 2 mg.

The preceding Phase 2 trial advanced more rapidly. Jastreboff and colleagues (NEJM 2023) assessed target doses of 1, 4, 8, and 12 mg. The higher dose groups followed an escalation of 2, 4, 8, 12 mg. This approach bypassed the 6 mg and 9 mg steps that the Phase 3 program later incorporated. This trial included 338 adults with obesity and spanned 48 weeks. Groups that escalated most rapidly to the highest doses also reported the greatest incidence of gastrointestinal issues.

Phase 3 introduced the 6 mg and 9 mg increments purposefully. A more gradual escalation distributes the dose increases over a longer timeframe, minimizing the leap between successive doses. Smaller increments alleviate gastrointestinal distress, such as nausea and vomiting, which typically intensifies immediately following a dosage increase. The Phase 2 trajectory of 2, 4, 8 doubled the dose across two consecutive steps. In contrast, the Phase 3 trajectory of 2, 4, 6, 9, 12 doubles only at the initial step, then progresses by 2 to 3 mg per subsequent step.

The practical insight from comparing these two dose escalation strategies is that the newer schedule prioritizes tolerability over speed. Although it takes a longer duration to attain 12 mg, fewer individuals discontinue the medication due to side effects during escalation. For a direct comparison, tirzepatide vs retatrutide comparison juxtaposes the two escalation schedules side by side.

The starting dose in every Retatrutide trial was 2 mg once weekly. This dosage is the baseline standardized by the Phase 3 program, with no lower entry point approved, as the drug itself lacks approval. Although some community users initiate below this dose, covered later, no official trial has done so.

The rationale for slow escalation is rooted in pharmacokinetics. Retatrutide exhibits a half-life of approximately six days, long enough to support once-weekly dosing. A drug typically reaches steady state, where the intake and clearance balance, after about five half-lives. For Retatrutide, this equates to roughly four to five weeks. The same six-day half-life accounts for the weekly dosing regimen, as a single injection suffices for the entire week. Each dose is maintained for about four weeks, allowing blood levels to plateau before the next increase. This avoids layering a higher dose onto still-rising levels.

Gastrointestinal side effects are dose-dependent, primarily occurring during dose escalation rather than at steady maintenance. Nausea, vomiting, diarrhea, and constipation tend to present shortly after an increase in dose, usually subsiding as the body acclimates. The NEJM Phase 2 trial found that a lower starting dose and slower titration reduced these gastrointestinal events in contrast to more rapid escalations to the same target dose.

The approach remains consistent across trials despite variations in exact rates: begin with a low dose, increase slowly, improving gastrointestinal tolerance. This strategy indicates that the schedule is not intended to be expedited. If side effects intensify at any given dose, prolonging that step for a few additional weeks is advisable rather than adhering rigidly to a calendar-based progression. Clinicians may extend a step to six or eight weeks if nausea persists, delaying the top dose but ensuring continued drug administration. Achieving steady tolerance is more beneficial than hastening to the top dose.

Maintenance is administered at either 9 mg or 12 mg once weekly, with 12 mg being the highest dosage used in trials. Some individuals maintain at 9 mg if they experience undesirable side effects at the maximum dose. The difference in weight loss between 9 mg and 12 mg is less pronounced than at lower dosages.

Weight loss corresponds to the maintenance dose. Lilly's Phase 3 TRIUMPH-1 trial was conducted over 80 weeks, reporting outcomes through two distinct estimands, which is more significant than it initially appears. The efficacy estimand assumes participants remained on treatment throughout. Under this measure, average weight loss achieved 19.0% at 4 mg, 25.9% at 9 mg, and 28.3% at 12 mg.

The treatment-regimen estimand includes all participants, even those who discontinued early for any reason. This resulted in lower figures of 17.6%, 23.7%, and 25.0% for the same doses. These estimands address different inquiries, rendering any weight loss statistic meaningful only when the estimand type is known. Headlines often cite the higher efficacy-estimand number without clarification.

For additional context, the earlier Phase 2 trial demonstrated a 24.2% mean weight loss at 12 mg by week 48 (Jastreboff et al., NEJM 2023). The Phase 3 trial figures were higher partly due to its extended duration.

The benefits diminish with increasing doses. Transitioning from 4 mg to 9 mg yields a substantial increase in weight loss. However, increasing from 9 mg to 12 mg results in only slight additional weight loss, while nausea, vomiting, and other side effects escalate with each increase. This trade-off is why many individuals consider 9 mg an acceptable endpoint instead of advancing to 12 mg. It is important to note that all TRIUMPH-1 figures originate from Lilly's topline release and have not undergone peer review or full publication. The best peptides for weight loss guide places these results within the broader context.

This section addresses the reconstitution process for Retatrutide, an investigational compound intended for research use. Retatrutide is not available as a ready-to-inject prescription product, hence there is no manufacturer-provided syringe, pre-filled pen, or standardized concentration. The calculations provided here serve as a guide for interpreting a dosing chart and are not intended to instruct self-dosing.

Retatrutide is supplied as a lyophilized powder that must be reconstituted with bacteriostatic water prior to dose measurement. The final concentration is determined by the volume of water added. A 10 mg vial with 2 mL of bacteriostatic water results in 5 mg/mL. Adding only 1 mL to the same vial yields 10 mg/mL, creating a more concentrated solution, which requires fewer syringe units per dose.

The unit calculation for a U-100 insulin syringe is based on a specific formula: units = (dose in mg ÷ concentration in mg/mL) × 100. Applying this to the 5 mg/mL scenario: a 2 mg dose equates to 40 units, a 4 mg dose equates to 80 units, and a 6 mg dose equates to 120 units. The 120-unit measurement exceeds the capacity of a standard 100-unit syringe, necessitating two draws. If the vial is mixed at 10 mg/mL, a 2 mg dose requires 20 units, as the increased concentration compacts the dose into a smaller volume. Incorrect concentration adjustments are a common source of error in reconstitution.

Storage protocols for reconstituted peptides apply here: maintain at 2 to 8 °C, shield from light, and avoid freezing or shaking to prevent peptide degradation. Conventionally, reconstituted Retatrutide is considered viable for approximately 28 days under refrigeration, a timeframe based on community usage rather than formal stability data. The retatrutide dosage calculator assists with these calculations by allowing entry of vial size, water volume, and target dose to determine the precise units required.

No official missed-dose instructions exist for Retatrutide, as an investigational drug does not carry an FDA label to provide such guidelines. A reasonable comparison can be made with the handling of missed doses for approved once-weekly incretin drugs, given that Retatrutide has a similar weekly administration schedule and half-life.

The general protocol for weekly GLP-1 class drugs suggests the following. If a missed dose is remembered within approximately four days (96 hours), administer it, then proceed with the regular weekly schedule. If more than four days have elapsed, skip the missed dose and resume the regimen at the next scheduled dosage. Avoid taking two doses close together, as this can cause a spike in drug levels and increase the risk of nausea and vomiting that the gradual titration aims to prevent.

Pharmacokinetically, there is reassurance. With a half-life of about six days, missing a single week does not significantly alter the steady-state level. A skipped injection does not warrant correction with a double dose. Consistency in weekly administration is more essential than any individual injection. Selecting a fixed injection day and setting a weekly reminder can help circumvent the issue entirely. For those adhering to a protocol, logging each dose on the day of administration eliminates uncertainty about skipped weeks. If missed doses become recurrent rather than isolated incidents, it is advisable to consult a clinician, as deviations from the schedule alter the exposure assumed by the titration process.

Everything in this section represents community practices, without backing from formal trials. These approaches were not tested in retatrutide studies and should not be interpreted as clinical guidance. They are anecdotal reports from users.

Some individuals opt to divide the weekly retatrutide dose into two or three smaller injections throughout the week, with a common pattern being a Monday and Thursday schedule. The reasoning is that a single large weekly injection can cause a sharp peak in drug level, which is thought to contribute to the severity of nausea. Distributing the total weekly dose over two or three injections is believed to mitigate this peak. Modeled peak reductions of approximately 28% for twice-weekly dosing and up to about 48% for daily dosing are often mentioned. These figures are extrapolated from pharmacokinetic models of semaglutide and tirzepatide and have not been verified for retatrutide. Whether the same calculations apply to a triple agonist remains uncertain. Splitting doses also results in more injections per week, presenting additional opportunities for contamination and dosing errors.

Sub-milligram dosage initiation is another community practice. Some start at 0.25 mg to 0.5 mg weekly, significantly lower than the 2 mg minimum used in all trials. This approach aims to reduce nausea during the initial phase of treatment. The rationale is clear, as nausea often peaks in the early weeks. However, it is unknown if 0.25 mg has any effect in humans at these low doses. There is no published evidence to support starting at such low doses, nor is there evidence to suggest it influences long-term outcomes.

Both practices remain unverified. Individuals who attempt them share experiences, but no controlled trials have validated their efficacy. Anyone considering splitting or micro-dosing is effectively experimenting with an unapproved drug, a decision that should be discussed with a clinician, rather than in an online forum.

Some histories make rapid escalation, or any use, inadvisable. Retatrutide has never carried an FDA label, yet the approved drugs in its class do, and their warnings provide a reasonable reference.

A personal or family history of medullary thyroid carcinoma or MEN2 (multiple endocrine neoplasia type 2) serves as the strongest contraindication. The entire incretin class carries a boxed warning for thyroid C-cell tumors based on rodent studies, and retatrutide acts on the same receptors. A history of pancreatitis also warrants caution. Similarly, pregnancy or breastfeeding are situations where the drug should be avoided entirely due to the lack of safety data.

Certain conditions necessitate caution rather than an outright avoidance. These include type 1 diabetes, severe gastroparesis, gallbladder disease, and severe kidney or liver impairment. The drug's effects on digestion and glucose levels can exacerbate these conditions, so careful medical oversight is essential during escalation.

Drug interactions are particularly significant for those on glucose-lowering medications. When retatrutide is combined with insulin and sulfonylureas, the risk of hypoglycemia increases, often necessitating a dose reduction of these medications when introducing a GLP-1 class drug. Retatrutide also slows gastric emptying, affecting the absorption rate of oral drugs. This is important to monitor with narrow-margin medications like warfarin and digoxin. It can diminish the absorption of oral contraceptives, making it advisable to discuss alternative methods with a healthcare provider.

Baseline and periodic monitoring are prudent for anyone increasing their dose. Blood glucose levels should be monitored in diabetics, and severe abdominal pain requires immediate evaluation, as it may indicate pancreatitis. These guidelines do not replace clinical judgment but highlight areas of concern based on class-level data.

One overarching rule applies: if a patient experiences significant gastrointestinal intolerance at a particular dose, they should maintain that dose or reduce it, rather than proceeding to the next level. The dosing schedule is a guideline, not a strict timetable. For complete safety information, refer to retatrutide side effects and the specific details in mood and emotional effects. The retatrutide overview provides insights into the mechanism and study background.